Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 1.00 |
| ▸ | PLAU | P00749 | 14/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 14/20 | 1.00 |
| ▸ | PLAT | P00750 | 13/20 | 1.00 |
| ▸ | F10 | P00742 | 12/20 | 1.00 |
| ▸ | PLG | P00747 | 10/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 7/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 7/20 | 1.00 |
| ▸ | F7 | P08709 | 6/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 5/20 | 1.00 |
| ▸ | HPN | P05981 | 4/20 | 0.70 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.70 |
| ▸ | F3 | P13726 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29682938 | 1.00 | F2 (1.00) | F2PLAUPRSS1PLATF10 | |
| SCHEMBL6292958 | 0.87 | F2 (1.00) | F2PLAUPRSS1PLATF10 | |
| SCHEMBL1325228 | 0.85 | PLAU (0.74) | F2PLAUPRSS1PLATF10 | |
| SCHEMBL23752572 | 0.84 | F2 (0.78) | F2PLAUPRSS1PLATF10 | |
| SCHEMBL13208176 | 0.84 | F2 (1.00) | F2PLAUPRSS1PLATF10 | |
| SCHEMBL4995709 | 0.83 | F2 (1.00) | F2PLAUPRSS1PLATF10 | |
| SCHEMBL18817939 | 0.82 | HPN (1.00) | F2PLAUPRSS1PLATF10 | |
| SCHEMBL6690412 | 0.82 | F7 (1.00) | F2PLAUPRSS1PLATF10 | |
| SCHEMBL7484247 | 0.82 | F2 (0.71) | F2PLAUPRSS1PLATF10 | |
| SCHEMBL4321170 | 0.81 | PLAU (1.00) | F2PLAUPRSS1PLATF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | claimed |
| EP-1140859-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035886-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | claimed |
| EP-2982668-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | Pharmacyclics LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9181280-B2 | Factor VIIa inhibitor | PHARMACYCLICS LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9162986-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS LLC (US) | 2015-10-20 | — | — | US | disclosed |
| EP-1569912-B1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS LLC | 2014-12-25 | — | — | US | disclosed |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8778625-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8729117-B2 | Factor VIIa inhibitor | PHARMACYCLICS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20080275250-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1761504-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2007-03-14 | — | — | EP | disclosed |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | PHARMACYCLICS LLC | 2006-09-14 | — | — | US | disclosed |
| WO-2005118554-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1569912-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| WO-2004050637-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-1140859-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035886-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | F7, F9, F5 | F2 10/4885PLAU 210/4885PRSS1 138/4885 |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | F2 16/4885PLAU 37/4885PRSS1 231/4885 |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | F2 17/4885PLAU 37/4885PRSS1 391/4885 |
| US-20080275250-A1 | Factor Viia Inhibitor | F7, F9, F5 | F2 16/4885PLAU 37/4885PRSS1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.